[Federal Register Volume 78, Number 101 (Friday, May 24, 2013)]
[Notices]
[Pages 31554-31555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-12406]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-13-0612]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-639-7570 or 
send comments to Ron Otten, 1600 Clifton Road, MS-D74, Atlanta, GA 
30333 or send an email to [email protected].
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Well-Integrated Screening and Evaluation for Women Across the 
Nation (WISEWOMAN) Reporting System (OMB 0920-0612, exp. 1/31/
2014)--Revision--National Center for Chronic Disease Prevention and 
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention 
(CDC).

Background and Brief Description

    Cardiovascular disease (CVD), which includes heart disease, 
myocardial infarction, and stroke, is the leading cause of death for 
women in the United States, and is largely preventable. The WISEWOMAN 
program (Well-Integrated Screening and Evaluation for Women Across the 
Nation), administered by the Centers for Disease Control and Prevention 
(CDC), was established to examine ways to improve the delivery of 
services for women who have limited access to health care and elevated 
risk factors for CVD. The program focuses on reducing CVD risk factors 
and provides screening services for select risk factors such as 
elevated blood cholesterol, hypertension and abnormal blood glucose 
levels. The program also provides women with referrals to lifestyle 
programs and medical care. The WISEWOMAN program currently provides 
services to approximately 45,000 women who are jointly enrolled in the 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP), 
also administered by CDC. The current cooperative agreements for 
WISEWOMAN awardees end June 30, 2013 and final submissions to CDC are 
due no later than October 31, 2013. CDC obtained OMB approval to 
collect information from these awardees through the ``WISEWOMAN 
Reporting System,'' OMB No. 0920-0612, exp. 1/31/2014. The information 
submitted to CDC includes semi-annual progress reports and minimum data 
elements (MDE) that are also submitted twice per year.
    The WISEWOMAN program will continue under a new set of four-year 
cooperative agreements that begin July 1, 2013 and end June 30, 2017. 
The new funding period will reflect an increased emphasis on efficient 
oversight of program awardees and documenting program outcomes. As a 
result, the WISEWOMAN information collection will be revised to support 
updated program goals. Changes to be implemented in the new cooperative 
agreement funding cycle include a reduction in the frequency of 
progress report submission--from twice per year to once per year--and 
changes to the content of the MDE submissions. The first reports based 
on the revised reporting requirements will be submitted to CDC in April 
2014.
    The hardcopy progress report provides a narrative summary of each 
awardee's objectives and the activities undertaken to meet program 
goals, including public education and outreach. The estimated burden 
per response is 8 hours. In the new cooperative agreement cycle, the 
frequency of response will decrease from twice per year to once per 
year, resulting in a net decrease in respondent

[[Page 31555]]

burden for progress reporting. In the future, CDC may transition from a 
hardcopy report to MIS-based progress reporting.
    The MDE information submitted to CDC includes baseline and follow-
up data (12 months post enrollment) for all women served through the 
WISEWOMAN program. The MDE describe risk factors for the women served 
in each program and the number and type of lifestyle program sessions 
they attend. The information allows CDC to assess the effectiveness of 
the WISEWOMAN program in reducing the burden of cardiovascular disease 
risk factors among women who utilize program services. MDE information 
may also be utilized in assessments of WISEWOMAN program impact and 
cost-effectiveness. MDE information has previously been submitted to 
CDC in two electronic transmissions: the burden for Screening and 
Assessment MDE was estimated at 16 hours per response and the burden 
for Lifestyle Intervention MDE was estimated at 8 hours per response. 
Under the new WISEWOMAN cooperative agreements, the MDE will be 
submitted as a single electronic file with a combined estimated burden 
per response of 24 hours. The total number of MDE variables will 
increase from 66 to 87. The number of variables relating to Lifestyle 
Interventions will decrease and the number of variables relating to 
Screening and Assessment will increase.
    CDC will continue to use the information collected from WISEWOMAN 
awardees to support continuous program monitoring and improvement 
activities, evaluation, and assessment of program outcomes. The overall 
program evaluation is designed to demonstrate how WISEWOMAN can obtain 
more complete health data on vulnerable populations, promote public 
education about disease incidence, cardiovascular disease risk-factors, 
health promotion, to improve the availability of screening and 
diagnostic services for under-served women, ensure the quality of 
services provided to under-served women, and develop strategies for 
improved interventions.
    The estimated number of WISEWOMAN awardees is 21 but may be 
adjusted when new cooperative agreements are issued. Participation in 
this information collection is required as a condition of cooperative 
agreement funding. There are no costs to respondents other than their 
time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                                     Number of       Number of      burden per     Total burden
      Type of respondent            Form name       respondents    responses per   response  (in     (in hrs)
                                                                    respondent         hrs)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Grantees              Screening and                 21               2              24           1,008
                                 Assessment and
                                 Lifestyle
                                 Program MDEs.
                                Annual Progress               21               1               8             168
                                 Report.
                                                                                 -------------------------------
    Total.....................  ................  ..............  ..............  ..............           1,176
----------------------------------------------------------------------------------------------------------------


Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate 
Director for Science, Office of the Director, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-12406 Filed 5-23-13; 8:45 am]
BILLING CODE 4163-18-P